« Return to News | Drug Sponsors

Amgen to buy Pfizer plant, saving 280 jobs

Friday, March 11, 2011 01:53 PM

Amgen has agreed to buy a Pfizer manufacturing plant at Dun Laoghaire, County Dublin, securing 280 jobs in the process. The transaction is expected to close in the second quarter of the year, according to Fierce Pharma.

Under the agreement, 240 employees will transfer to Amgen; the other 40 will remain employed by Pfizer. Amgen will manufacture Pfizer's products at the facility for an interim period, and Pfizer will lease a portion of the facility from Amgen.

Amgen intends to develop the capability to formulate and fill its biological products at the site and expand manufacturing capabilities. The aseptic operations facility has freeze dry product and liquid vial filling operations.

"As we expand internationally, the Dublin site will help us deliver a growing supply of Amgen medicines for patients worldwide," Madhu Balachandran, senior vice president of Amgen Manufacturing, said in a statement issued by Ireland's Industrial Development Agency (IDA). "We are impressed with the technical expertise and commitment to excellence demonstrated by the employees who work at the Dun Laoghaire site and look forward to welcoming them to Amgen's global manufacturing team."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.